MODEX THERAPEUTICS LLC holds $103.5M across 1 federal awards, concentrated at Department of Health and Human Services (HHS). The prior award was single-bid — competitive dynamics may favor a challenge. Set-aside status: NONE. Recompete timing centers on the Feb 29, 2028 PoP end — agencies typically plan 12–18 months ahead.
ADVANCE THE DEVELOPMENT OF POTENT, CROSS-REACTIVE MULTISPECIFIC ANTIBODIES FOR THE PREP COUNTERMEASURE OF COVID-19 AND SEASONAL AND HIGHLY PATHOGENIC AVIAN INFLUENZA.
Current PoP ends Feb 29, 2028 (582 days remaining). Agencies typically plan 12–18 months ahead — capture window opens around Aug 29, 2026.
Track recompete timing in SCOUT →MODEX THERAPEUTICS LLC — $103.5M obligated across 1 awards (firm-wide, all agencies).
Query this award live in SCOUT via MCP — personalized scoring, watchlists, and capture workflow across the corpus. Learn about SCOUT MCP →
Live Demand-Fit + Displacement scoring, alerts on verdict flips, and watchlists. Free — no card required.
See all live recompete landscapes — who else is expiring, and where the openings are.
Open MODEX THERAPEUTICS LLC’s federal contract profile — agency mix, recompete pipeline, and teaming relationships.
Data: Showing contracts ≥ $100K from federal procurement records (FPDS-NG, SAM.gov, and related repositories), normalized by PrimeRFP SCOUT. Each row keyed by Award ID (PIID); task orders appear as independent rows. Register free to start exploring SCOUT →